Assessment of boron-containing compounds and Oleoylethanolamid supplementation in the treatment of COVID-19

Assessment of boron-containing compounds and oleoylethanolamide supplementation on the recovery trend in Patients with COVID-19: A double-blind randomized placebo-controlled clinical trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090609002017N35

Enrollment

Registered

2020-05-17

Start date

2020-05-19

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID - 19. Coronavirus infection, unspecified

Interventions

Intervention 1: Group 1 consume 2 capsules containing 5 mg boron containing compound per day for two weeks. Intervention 2: Group 2 consume 2 capsules containing 200 mg oleoylethanolamide per day fo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with Known COVID-19

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Recovery trend. Timepoint: At baseline and at the end of intervention. Method of measurement: Examination.;Hospital admission time. Timepoint: At baseline and at the end of intervention. Method of measurement: Observation.;CBC,ESR. Timepoint: At baseline and at the end of intervention. Method of measurement: Blood sampling and testing with H1 device.;CRP. Timepoint: At baseline and at the end of intervention. Method of measurement: Blood sampling and measurement with Auto analyzer device.	—

Measure

Time frame

Recovery trend. Timepoint: At baseline and at the end of intervention. Method of measurement: Examination.;Hospital admission time. Timepoint: At baseline and at the end of intervention. Method of measurement: Observation.;CBC,ESR. Timepoint: At baseline and at the end of intervention. Method of measurement: Blood sampling and testing with H1 device.;CRP. Timepoint: At baseline and at the end of intervention. Method of measurement: Blood sampling and measurement with Auto analyzer device.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Ostadrahimi

Tabriz University of Medical Sciences

ostadrahimi@tbzmed.ac.ir+98 41 1335 2292

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 25, 2026